Medicine and Dentistry
Oncology
96%
Non-Hodgkin Lymphoma
87%
Doxorubicin
62%
CHOP
58%
Vincristine
49%
Disease
49%
Cyclophosphamide
48%
Overall Survival
40%
Prednisone
39%
Neoplasm
37%
Diffuse Large B-Cell Lymphoma
34%
Radiation Therapy
31%
Follicular Lymphoma
29%
Progression Free Survival
27%
Hodgkin's Lymphoma
27%
Rituximab
25%
Large-Cell Lymphoma
25%
B Cell
23%
Phase II Trials
23%
Lymphoma
21%
Prognostic Factor
21%
Combination Chemotherapy
19%
Gene Expression
19%
T Cell
19%
Peripheral T-Cell Lymphoma
18%
Group Trial
17%
Clinical Trial
16%
Breast Cancer
15%
Tositumomab
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Cisplatin
13%
Bleomycin
11%
Etoposide
11%
Involved-Field Radiotherapy
11%
Gene Expression Profiling
11%
Chemotherapy Regimens
10%
Arm
10%
Survival Rate
10%
Methotrexate
9%
Patient with Non-Hodgkins Lymphoma
8%
Lymphocytic Lymphoma
8%
Histiocytic Lymphoma
8%
Radioimmunotherapy
8%
B-Cell Lymphoma
8%
Iodine 131
8%
Major Histocompatibility Complex
8%
Leukemia
7%
Recurrence Free Survival
7%
Large Cell
7%
Malignant Neoplasm
7%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Chemotherapy
84%
Doxorubicin
77%
Vincristine
69%
Cyclophosphamide
67%
Prednisone
51%
Disease
46%
Overall Survival
36%
Rituximab
29%
Progression Free Survival
29%
Methotrexate
27%
Remission
25%
Hodgkin Disease
25%
Phase II Trials
24%
Clinical Trial
23%
Bleomycin
22%
Follicular Lymphoma
20%
Neoplasm
19%
Tositumomab
19%
Etoposide
19%
Lymphoma
19%
Mantle Cell Lymphoma
13%
Diffuse Large B Cell Lymphoma
13%
Cisplatin
13%
Verapamil
13%
Iodine-131
12%
Breast Cancer
12%
Non Small Cell Lung Cancer
11%
Bisantrene
11%
Mitoxantrone
11%
Small Cell Lung Cancer
11%
Vindesine
11%
Chemotherapy Regimens
11%
Large Cell Lymphoma
11%
Survival Rate
9%
Cytarabine
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Malignant Neoplasm
8%
Mitomycin
8%
Adenocarcinoma
8%
Group Trial
7%
Recurrence Free Survival
7%
Docetaxel
7%
Galiximab
7%
Lymphocytic Lymphoma
7%
Esorubicin
7%
Alisertib
7%
Dexamethasone
7%
Monoclonal Antibody Ki 67
6%
Monoclonal Antibody
5%
Keyphrases
Southwest Oncology Group
82%
Group Studies
46%
Prednisone
41%
Diffuse Large B-cell Lymphoma (DLBCL)
39%
Cyclophosphamide
36%
Doxorubicin
31%
Chemotherapy
30%
Non-Hodgkin Lymphoma
26%
Overall Survival
25%
Follicular Lymphoma
22%
Progression-free Survival
21%
Complete Remission
20%
High-grade non-Hodgkin Lymphoma
19%
Lymphoma
19%
Phase II Trial
18%
Median Survival
17%
Phase II Study
16%
Methotrexate
15%
Combination Chemotherapy
15%
Etoposide
14%
Partial Response
14%
Complete Response
13%
Rituximab
13%
Mitomycin C
13%
Hodgkin Disease
12%
Lymphoma Patients
11%
Malignant Lymphoma
11%
Complete Response Rate
11%
Mitoxantrone
11%
Doxorubicin-cyclophosphamide
10%
Initial Treatment
10%
Cisplatin
10%
Unfavorable Histology
10%
Monoclonal Antibody
10%
Clinical Trials
10%
HLA-DR
9%
Radioimmunotherapy
9%
Prognostic Significance
9%
Bleomycin
9%
5-fluorouracil (5-FU)
9%
Advanced Stage
8%
Bis-pyrene
8%
Prognostic Factors
8%
Aggressive non-Hodgkin Lymphoma
8%
Outcome Prediction
8%
Molecular Diagnostics
8%
Mantle Cell Lymphoma
8%
Tositumomab
7%
Intermediate Grade
7%
Survival Prediction
7%